Interpace Biosciences Announces Full Year and Fourth Quarter 2020 Financial and Business Results
March 31, 2021 17:20 ET
|
Interpace Biosciences, Inc.
2020 Full Year Net Revenue of $32.4 Million Up 34% vs Prior Year; Fourth Quarter Net Revenue of $9.6M Million Up 129% vs Prior Year; Provides Full Year 2021 Range of RevenuesOn Target to Achieve...
Interpace Biosciences Announces Divestiture of New Haven CLIA lab to DiamiR
March 17, 2021 07:30 ET
|
Interpace Biosciences, Inc.
Part of Company’s Site Consolidation and Cost Savings Measures Parsippany, NJ, March 17, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTC: IDXG) announced today that it has entered into...
Interpace Biosciences Announces Contract for Thyroid Testing with Blue Cross Blue Shield of Illinois
February 25, 2021 16:31 ET
|
Interpace Biosciences, Inc.
In-network status for ThyGeNEXT® and ThyraMIR® with State’s Largest Payer PARSIPPANY, NJ, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or “the Company”), today...
Interpace Biosciences Announces Acceptance for Trading on the OTCQX
February 24, 2021 17:54 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace Biosciences” or the “Company”), an emerging leader in enabling personalized medicine, today...
Interpace Biosciences Announces Path Forward in Letter to Shareholders
February 16, 2021 21:21 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace”), a leader in enabling personalized medicine, issued the following communication to...
Interpace Biosciences Announces CFO Leadership Transition
February 04, 2021 16:42 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace”) a leader in enabling personalized medicine, announced today that its Board of Directors has...
Interpace Biosciences Announces License Agreement with Rutgers University and Mass General Hospital
February 01, 2021 09:27 ET
|
Interpace Biosciences, Inc.
Parsippany, NJ, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) announced today that it has executed a license agreement with Rutgers, The State University of New...
Interpace Biosciences Announces Contract for Thyroid Testing with Blue Cross Blue Shield of Florida
January 28, 2021 09:15 ET
|
Interpace Biosciences, Inc.
In-network status for ThyGeNEXT® and ThyraMIR® with State’s Largest Payer PARSIPPANY, NJ, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) announced today that the...
Interpace Biosciences Announces Third Quarter 2020 Financial and Business Results and Completion of $5 Million Bridge Loan
January 20, 2021 08:30 ET
|
Interpace Biosciences, Inc.
Third Quarter Net Revenue of $8.2 Million Up 7% vs Prior Year; Third Quarter Year to Date Net Revenue of $22.8 Million Up 14% vs Prior YearEstimates Fourth Quarter Net Revenue range of $9.0 million -...
Interpace Biosciences’ Audit Committee Investigation Finds Complaints Unsubstantiated
October 14, 2020 06:30 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (Nasdaq: IDXG) announced today that the Audit Committee of the Board of Directors has...